

VS-6063 IR tablet formulations
Percentage VS-6063 released (%)
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%
0
10
20
30
40
50
60
70
80
90
100
Time (Mins)
Reference formulation
(HMPC-AS DC tablet)
(HPMC-AS DG tablet)
(PVP VA/Soluplus DC tablet)
(PVP VA/Soluplus DG tablet)

FIG. 1



VS-6063 IR tablet formulations
Percentage VS-6063 released (%)
80.0%
70.0%
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%
0
20
40
60
80
100
Time (mins)
Reference formulation
(PVP VA/Soluplus DC tablet)
(PVP VA/Soluplus DG tablet hard ribbons)
(PVP VA/Soluplus DG tablet soft ribbons)
(PVP VA/Soluplus DG tablet soft ribbons + 3% crospovidone)

FIG. 2



VS-6063 IR tablet formulations
70.0%
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%
Percentage drug released (%)
0
10
20
30
40
50
60
70
80
90
100
Time (mins)
Reference formulation
(HMPC-AS DC tablet)
(HPMC-AS DG tablet)
(HPMC-AS DG tablet)
(HPMC-AS DG tablet)

FIG. 3



VS-6063 IR tablet formulations dissolution in 0.1M HCl
Percentage drug released (%)
100.0%
90.0%
80.0%
70.0%
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%
0
20
40
60
80
100
120
140
Time (mins)
(HPMC-AS DG tablet)
(HPMC-AS DG tablet)

FIG. 4



VS-6063
VS-6063-25% SDD in Soluplus/PVP-A
VS-6063-25% Phys Mix With Soluplus/PVP-A
VS-6063-10% SDD in EUDRAGIT L100-55
Concentration (ng/mL)
1600
1400
1200
1000
800
600
400
200
0
0
4
8
12
16
20
24
Nominal Time (hr post-dose)

FIG. 5



20 mg API/kg: VS-6063-25% Phys Mix with Soluplus/PVP-A
20 mg API/kg: VS-6063-25% SDD in Soluplus/PVP-A
10 mg API/kg: VS-6063-50% Phys Mix with Soluplus/PVP-A
20 mg API/kg: VS-6063-50% Phys Mix with Soluplus/PVP-A
Concentration (ng/mL)
1600
1400
1200
1000
800
600
400
200
0
0
4
8
12
16
20
24
Nominal Time (hr post-dose)

FIG. 6